SRR10899983
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- G2M_CHECKPOINT+0.500
- MITOTIC_SPINDLE+0.500
- TGF_BETA_SIGNALING+0.500
- MYC_TARGETS_V2+0.400
- ALLOGRAFT_REJECTION+0.300
- ANGIOGENESIS+0.300
- APICAL_JUNCTION+0.300
- IL6_JAK_STAT3_SIGNALING+0.300
Top 10 suppressed
- FATTY_ACID_METABOLISM-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- ADIPOGENESIS-0.300
- PANCREAS_BETA_CELLS-0.300
- PEROXISOME-0.300
- BILE_ACID_METABOLISM-0.200
- CHOLESTEROL_HOMEOSTASIS-0.200
- KRAS_SIGNALING_DN-0.200
- P53_PATHWAY-0.200
- ESTROGEN_RESPONSE_EARLY-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-A3IN-01A-11R-A20F-07 | — | — | 0.853 |
| 2 | TCGA-FD-A3B7-01A-31R-A20F-07 | — | — | 0.838 |
| 3 | SRR8518214 | — | D | 0.828 |
| 4 | TCGA-34-5239-01A-21R-1820-07 | — | cohortSQ1 | 0.827 |
| 5 | TCGA-37-A5EM-01A-21R-A27Q-07 | — | cohortSQ1 | 0.826 |
| 6 | TCGA-FD-A62S-01A-11R-A30C-07 | — | — | 0.819 |
| 7 | SRR934821 | — | — | 0.809 |
| 8 | TCGA-DK-A3WX-01A-22R-A22U-07 | — | — | 0.806 |
| 9 | SRR650185 | — | — | 0.800 |
| 10 | BS_NR3P3GN2 | high-grade glioma | — | 0.798 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.500 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |